Scenesse effective for Solar Urticaria

Written by on October 30, 2010 in Scenesse (Afamelanotide Implant 16mg) with 0 Comments

For those following the progress of the development of Scenesse (formerly Afamelanotide), some good results from Phase II trials in treating Solar Urticaria.

Solar Urticaria is a rare skin condition that can be thought of as being like hives caused my exposure to the sun.

Participants received a 16mg implant of Scenesse and were found to have both a significant increase in skin melanin and decrease in sensitivity to previously irritating wavelengths of light.

Systemic photoprotection in solar urticaria with α-melanocyte stimulating hormone analogue [Nle(4) -D-Phe(7) ]-α-MSH.

Conclusion: Melanisation following afamelanotide is accompanied by reduction in solar urticaria response across a broad spectrum of wavelengths. Further study is warranted to assess clinical benefit in under ambient conditions in summertime.

Although not directly related to rosacea it does show that Scenesse is continuing its slow but steady progress towards proving that it is a safe and effective photoprotective treatment.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.